logo

For the Inventor, By the Inventor

Hyderabad Telangana, India

Natco Pharma Limited


USPTO Granted Patents = 51

% Expired Patents = 27.5



Forward Citations = 50

Loading Chart...
Loading Chart...

93 inventors (with patents filed for the assignee):

goldMedal Venkaiah Chowdary Nannapaneni (28 out of 28 patents)

silverMedal Nannapaneni Venkaiah Chowdary (22 out of 22 patents)

bronzeMedal Bhujanga Rao Adibhatla Kali Satya (16 out of 16 patents)

4.  Durga Prasad Konakanchi (14 out of 15 patents)

5.  Pulla Reddy Muddasani (12 out of 12 patents)

6.  Kali Satya Bhujanga Rao Adibhatla (11 out of 11 patents)

7.  Amala Kompella (10 out of 10 patents)

8.  Sreenivas Rachakonda (10 out of 10 patents)

9.  Ramanadham Jyothi Prasad (8 out of 8 patents)

10.  Buchappa Gongalla (6 out of 6 patents)

11.  Srinivasa Krishna Murthy Konduri (5 out of 5 patents)

12.  Venugopala Krishna Gampa (5 out of 5 patents)

13.  Bollepalli Nageshwara Rao (4 out of 4 patents)

14.  Janaki Rama Rao Ravi (3 out of 3 patents)

15.  Uma Naresh Babu Kotra (3 out of 3 patents)


Core Competencies:
Venetoclax
Ibrutinib
Eribulin
Acalabrutinib
Sugammadex
Cabozantinib
Pomalidomide
Nilotinib
Lacosamide
Sunitinib
Phenylaminopyrimidine
Quinazoline

51 patents:

1. 12729197 - Process for the preparation of venetoclax and its polymorphs thereof (2026-09-08),
2. 12534467 - Process for the preparation of Acalabrutinib (2026-01-27),
3. 12522611 - Process for the preparation of high pure Eribulin and its Mesylate salt (2026-01-13),
4. 11845811 - Process for the preparation of Sugammadex sodium and its novel polymorphic form (2023-12-19),
5. 11730753 - Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride (2023-08-22),
6. 11576917 - Pharmaceutical compositions comprising Ibrutinib (2023-02-14),
7. 11498902 - Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof (2022-11-15),
8. 11465988 - Process for the preparation of Tipiracil hydrochloride and intermediates thereof (2022-10-11),
9. 11452722 - Stable pharmaceutical compositions comprising lenalidomide (2022-09-27),
10. 11414421 - Process for the preparation of ribociclib succinate and its novel crystalline forms thereof (2022-08-16),
11. 11111228 - Process for the preparation of pomalidomide and its purification (2021-09-07),
12. 11091470 - Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride (2021-08-17),
13. 11008296 - Intermediates for the preparation of eribulin thereof (2021-05-18),
14. 10966971 - Pharmaceutical compositions of pomalidomide (2021-04-06),
15. 10870650 - Process for the preparation of amorphous idelalisib (2020-12-22),
Natco Pharma Limited, headquartered in Hyderabad, Telangana, specializes in the development and manufacture of pharmaceutical compositions. The company focuses on innovative therapies, particularly in oncology and other therapeutic areas, with a strong portfolio that includes advanced treatments such as Venetoclax, Ibrutinib, and Eribulin. Natco is committed to enhancing patient care through research-driven solutions and aims to expand its global footprint in the pharmaceutical industry.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Natco Pharma Limited
51 Patents

#4 in Hyderabad Telangana

#39 in India

#13,766 in the World

Hyderabad Telangana, IN
Hyderabad Telangana, India

Natco Pharma Limited

Forward Citations = 50

93 inventors:

goldMedal Venkaiah Chowdary Nannapaneni (28 out of 28 patents)

silverMedal Nannapaneni Venkaiah Chowdary (22 out of 22 patents)

bronzeMedal Bhujanga Rao Adibhatla Kali Satya (16 out of 16 patents)

4.  Durga Prasad Konakanchi (14 out of 15 patents)

5.  Pulla Reddy Muddasani (12 out of 12 patents)

Please report any incorrect information to [email protected]
Loading…